| Patient | Martha Canary |
|---|---|
| Date of birth | 1856-05-01 |
| Identifiers | MRN HR-NI008-SYN-TD; SSN (made up) 000-08-9532 |
| Document date | 1901-03-30 |
| Author | Ruth Ann Kessler, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week review: naltrexone, liver stiffness, mood and benefits. [S]
Ms. Canary returns four weeks after intake. She has had no alcohol. Her tooth was removed at the dental clinic the day after her sick visit, and she finished the amoxicillin; the pain and swelling are gone. She has missed about eight of the last 21 naltrexone tablets: a bottle was lost when she moved her things, and some days she forgot. Cravings are milder on the days she takes it. She has had no nausea or stomach pain. She sleeps five to six hours and her mood is better. Her Medicaid and SNAP have been approved. She has called the peer recovery specialist twice and went to one women's meeting. [S]
| Element | Detail |
|---|---|
| Alcohol | None for four weeks |
| Naltrexone | About eight of 21 doses missed; no side effects |
| Dental abscess | Tooth removed; healed |
| Mood | PHQ-9 9; GAD-7 7 |
| Benefits | Medicaid and SNAP approved |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; weight rising |
| Ears, nose, mouth, and throat | Negative | Jaw pain and swelling gone |
| Gastrointestinal | Negative | No nausea, abdominal pain or yellowing |
| Psychiatric | Positive | Some low days; cravings milder; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Gabapentin 300 mg oral capsule on a written five-day schedule for alcohol withdrawal: 300 mg in the morning, 300 mg in the afternoon and 600 mg at bedtime for three days, then 300 mg twice daily on day four, 300 mg at bedtime on day five, then stop; dispensed for the five days only | Per the written five-day schedule | Oral route | 1901-03-02 to 1901-03-06 | completed | S |
| Thiamine 100 mg by intramuscular injection once daily for three days, given in the clinic | 100 mg intramuscularly once daily for three days | Intramuscular route | 1901-03-02 to 1901-03-04 | completed | S |
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1901-03-05 | active | S |
| Folic acid 1 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1901-03-02 | active | S |
| Potassium chloride extended-release 20 mEq oral tablet, one tablet daily with food for five days | One tablet daily with food for five days | Oral route | 1901-03-02 to 1901-03-06 | completed | S |
| Magnesium oxide 400 mg oral tablet, one tablet twice daily for two weeks | One tablet twice daily for two weeks | Oral route | 1901-03-02 to 1901-03-16 | completed | S |
| Naltrexone 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1901-03-09 to 1901-03-30 | completed | S |
| Extended-release naltrexone 380 mg by deep intramuscular injection into the buttock every four weeks, given by the clinic nurse | 380 mg intramuscularly every four weeks | Intramuscular route | 1901-03-30 | active | S |
| Amoxicillin 500 mg oral capsule, one capsule three times daily for five days | One capsule three times daily for five days | Oral route | 1901-03-23 to 1901-03-28 | completed | S |
| Ibuprofen 400 mg oral tablet, one tablet with food every 8 hours as needed for tooth pain, for up to five days | One tablet with food every 8 hours as needed, up to five days | Oral route | 1901-03-23 to 1901-03-28 | completed | S |
| Acetaminophen 500 mg oral tablet, one tablet every 6 hours as needed with the ibuprofen, no more than 2,000 mg a day, for up to five days | One tablet every 6 hours as needed, no more than 2,000 mg a day | Oral route | 1901-03-23 to 1901-03-28 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1901-03-30 | Body height | 165 | cm | S |
| 1901-03-30 | Body weight | 50.9 | kg | S |
| 1901-03-30 | Body mass index (BMI) [Ratio] | 18.7 | kg/m2 | S |
| 1901-03-30 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1901-03-30 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1901-03-30 | Heart rate | 78 | /min | S |
| 1901-03-30 | Respiratory rate | 16 | /min | S |
| 1901-03-30 | Body temperature | 36.7 | Cel | S |
| 1901-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1901-03-30 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 1901-03-30 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 100 | fL | 80-100 fL | Normal | S |
| 1901-03-30 | Platelets [#/volume] in Blood by Automated count | 191 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1901-03-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 10-35 U/L | High | S |
| 1901-03-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 7-35 U/L | Normal | S |
| 1901-03-30 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 132 | U/L | 5-40 U/L | High | S |
| 1901-03-30 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 1901-03-30 | Phosphatidylethanol [Mass/volume] in Blood | 24 | ng/mL | <=20 ng/mL | High | S |
| 1901-03-30 | Liver stiffness by US.transient elastography | 9.6 | kPa | <=8 kPa | High | S |
| 1901-03-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 1901-03-30 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S |
Vital signs recorded on 1901-03-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 122/78, pulse 78; weight 50.9 kg, BMI 18.7 |
| Mouth | Extraction socket healing cleanly |
| Abdomen | Soft and non-tender; no ascites |
| Skin | No jaundice, spider angiomas or palmar erythema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alcohol use disorder, severe (nine of eleven DSM-5-TR criteria), daily drinking of about a pint of whiskey with heavier binges for many years; synthetic modern episode linked to her documented lifelong heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding; DSM-5-TR severe alcohol use disorder maps to F10.20 when withdrawal is coded separately. Person-first language; not a claim about her real diagnosis. |
| Alcohol withdrawal, mild, at low risk of complications (PAWSS 3, CIWA-Ar 9 at intake; no past seizures or delirium tremens), managed as an outpatient with daily nurse checks | resolved | confirmed | F10.230 | S — Synthetic withdrawal episode; resolved by the one-week visit. |
| Raised liver enzymes (AST 96, ALT 44, GGT 240 U/L) with a FIB-4 index of 3.93, above the cut point for possible advanced fibrosis; liver stiffness measurement planned | resolved | confirmed | R74.01 | S — Synthetic presenting finding; superseded when elastography and the clinical picture supported alcohol-associated steatotic liver disease. |
| Alcohol-associated steatotic liver disease, without cirrhosis: liver stiffness 9.6 kPa after four weeks without alcohol, falling enzymes, normal bilirubin, albumin, INR and platelets | active | confirmed | K70.0 | S — Synthetic modern diagnosis made at the four-week visit. |
| Depressive symptoms during heavy drinking (PHQ-9 14, item 9 scored 0); whether they are alcohol-induced or an independent depression to be judged after two to four weeks without alcohol | active | provisional | F32.A | S — Synthetic provisional finding; resolved as the PHQ-9 fell to 5 after ten weeks without alcohol, consistent with alcohol-induced depressive symptoms. Not a claim about her real mood. |
| Daily chewing tobacco for many years; not ready to stop at intake | active | confirmed | F17.220 | S — Synthetic modern coding anchored to the documented chewing tobacco. |
| Underweight (BMI 18.4) with poor food intake, low folate, magnesium and phosphate, and slightly low albumin | active | confirmed | R63.6 | S — Synthetic finding anchored to a contemporary impression of poor nutrition (R). |
| Housing instability: staying in a spare room at a friend's house, with nowhere to go if that ends; has stayed in shelters in past winters | active | confirmed | Z59.811 | S — Synthetic social need anchored to her documented poverty and moves from town to town. |
| Food insecurity: often goes without meals at the end of the month | active | confirmed | Z59.41 | S — Synthetic social need anchored to her documented poverty. |
| Periapical abscess of a lower left molar with facial swelling and low-grade fever, on naltrexone; treated without opioids, tooth removed at the dental clinic the next day; resolved | resolved | confirmed | K04.7 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Drinking since the last visit (her own account, day by day), cravings and triggers | Every visit | Completed today | No alcohol for four weeks; cravings milder |
| Laboratory | PEth, explained as part of care and not as a test of honesty | At baseline and about every one to two months | Completed today | 24 ng/mL, from 820 |
| Laboratory | Thiamine, folate and electrolytes | Thiamine before glucose and through recovery; electrolytes rechecked within a week if low | Completed today | Thiamine and folic acid daily; hemoglobin 12.6 g/dL, MCV 100 fL |
| Medication safety | Medicine for alcohol use disorder: adherence, side effects, opioid exposure | Every visit | Completed today | About eight of 21 oral doses missed; no side effects; changed to the monthly injection today |
| Laboratory | Liver enzymes on naltrexone | Baseline, within the first months of treatment, then periodically | Completed today | AST 48, ALT 33, GGT 132 U/L on naltrexone, all falling |
| Imaging | Liver fibrosis: FIB-4, transient elastography, albumin, INR, platelets | Elastography when FIB-4 is above 2.67, repeated after months without alcohol | Completed today | Liver stiffness 9.6 kPa; albumin 3.6 g/dL; platelets 191; FIB-4 1.92 |
| Examination | Weight, meals and food access | Every visit | Completed today | Weight 50.9 kg, BMI 18.7; two meals a day on most days |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcohol | At baseline, after two to four weeks without alcohol, then at least monthly while symptoms persist | Completed today | PHQ-9 9, item 9 scored 0; GAD-7 7 |
| Survey | Suicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; rifle stored; 988 card carried |
| Self-management | Peer recovery support and mutual-help meetings | Weekly peer contact; meetings of her choice | Completed today | Two calls with the peer specialist; one women's meeting |
| Self-management | Housing, food, income and health coverage | Every visit | Completed today | Medicaid and SNAP approved; on the housing program waiting list |
| Self-management | Chewing tobacco | Every visit | Completed today | Still chewing; not ready to stop |
| Medication safety | Naloxone | Reassess at every visit | Not indicated | No opioid use; she turned down pain pills offered to her |
Goal progress:
Guideline basis: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The Healthcare Professional's Core Resource on Alcohol (2026); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Preventive visit in four weeks with the second naltrexone injection and vaccines. Ten-week review in six weeks. Weekly peer contact. Next scheduled visit 1901-04-27: periodic adult preventive visit. [S]